Indian biotech firm develops world’s first, indigenous Bi-Specific 3rd generation CAR T cells for cancer treatment

Q: How long will it take to read this news story?

The story "Indian biotech firm develops world’s first, indigenous Bi-Specific 3rd generation CAR T cells for cancer treatment" has 1087 words across 24 sentences, which will take approximately 5 - 10 minutes for the average person to read.

Q: Which news outlet covered this story?

The story "Indian biotech firm develops world’s first, indigenous Bi-Specific 3rd generation CAR T cells for cancer treatment" was covered 8 hours ago by Economic Times, a news publisher based in India.

Q: How trustworthy is 'Economic Times' news outlet?

Economic Times is a fully independent (privately-owned) news outlet established in 1961 that covers mostly business news. The outlet is headquartered in India and publishes an average of 6 news stories per day. It's most recent story was published 10 hours ago.

Q: What do people currently think of this news story?

The sentiment for this story is currently Positive, indicating that people regard this as "good news".

Q: How do I report this news for inaccuracy?

You can report an inaccurate news publication to us via our contact page. Please also include the news #ID number and the URL to this story.<ul><li>News ID: #27148596</li><li>URL: https://chronographically.beamstart.com/news/indian-biotech-firm-develops-worlds-17423000538055</li></ul>

Economic Times Logo Economic Times 8h ago

Indian biotech firm develops world’s first, indigenous Bi-Specific 3rd generation CAR T cells for cancer treatment - Economic Times

Quick Summary:

This therapy targets multiple tumor-specific antigens, offering improved treatment precision for blood cancer patients, and significantly reducing costs, thus enhancing accessibility in India and globally.

"This approval is a testament to India’s growing expertise in cutting-edge biotechnology and precision medicine,” said Dr Gaurav Kharya, a clinician and founder of Cellogen Therapeutics, in a statement.“Developing this CAR T product required three years of relentless research and hard work.

Delhi-based biotech startup Cellogen Therapeutics has secured regulatory approval for the patent of the world’s first, indigenously developed Bi-Specific 3rd Generation Chimeric Antigen Receptor T (CAR T) cells.